PYC Stock Overview
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PYC Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.20 |
| 52 Week Low | AU$0.055 |
| Beta | 0.71 |
| 11 Month Change | 37.93% |
| 3 Month Change | 81.82% |
| 1 Year Change | 244.83% |
| 33 Year Change | 37.93% |
| 5 Year Change | 207.69% |
| Change since IPO | -23.08% |
Recent News & Updates
Recent updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10
Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully
Jul 03Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Jan 25Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Jul 31We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
Mar 28Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Feb 20
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?
Jan 26What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition
Dec 22We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth
Nov 17Shareholder Returns
| PYC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 0.6% |
| 1Y | 244.8% | 32.6% | 19.9% |
Return vs Industry: PYC exceeded the Australian Biotechs industry which returned 32.6% over the past year.
Return vs Market: PYC exceeded the Australian Market which returned 19.9% over the past year.
Price Volatility
| PYC volatility | |
|---|---|
| PYC Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: PYC's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: PYC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Rohan Hockings | pyctx.com |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.
PYC Therapeutics Limited Fundamentals Summary
| PYC fundamental statistics | |
|---|---|
| Market cap | AU$933.22m |
| Earnings (TTM) | -AU$37.73m |
| Revenue (TTM) | AU$22.06m |
42.3x
P/S Ratio-24.7x
P/E RatioIs PYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYC income statement (TTM) | |
|---|---|
| Revenue | AU$22.06m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$22.06m |
| Other Expenses | AU$59.78m |
| Earnings | -AU$37.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0081 |
| Gross Margin | 100.00% |
| Net Profit Margin | -171.02% |
| Debt/Equity Ratio | 0% |
How did PYC perform over the long term?
See historical performance and comparison